Search | Clinical Trials Finder

Conditions: Chronic Hepatitis C Infection
Interventions: Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV); Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 13
States / cities: Rialto, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Chronic Hepatitis C Infection, Fatty Liver
Interventions: Rosiglitazone and Pegasys/Ribavirin; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 31
States / cities: North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more

Conditions: Hepatitis C, Chronic
Interventions: GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 21
States / cities: Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127, Faldaprevir (BI 201335); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 24
States / cities: Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more

Conditions: Hepatitis C Virus
Interventions: BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more

Conditions: Chronic Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: CDI-31244, SOF/VEL; Drug
Lead sponsor: Cocrystal Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Hepatitis C
Interventions: albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more

Conditions: Hepatitis C
Interventions: TT-034; Drug
Lead sponsor: Tacere Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: San Diego, California • Durham, North Carolina • Dallas, Texas + 1 more

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 26
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more

Conditions: Chronic Hepatitis C
Interventions: Peginterferon, Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO5024048, danoprevir, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 19
States / cities: La Jolla, California • Long Beach, California • Sacramento, California + 15 more

Conditions: Chronic Hepatitis C Virus Infection
Interventions: ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Nitazoxanide With Pegylated Interferon And Ribavirin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: SCV-07; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, Ribavirin, Ritonavir; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more

Conditions: HCV Infection
Interventions: placebo, ANA598, Peginterferon, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • San Clemente, California + 17 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Search by objective public record fields.

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072